SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma

BMC Cancer

Table 1 Mutual-exclusivity analysis between SNCA and multiple-immune checkpoints in LUAD

A	B	Neither	Log2 Odds Ratio	p-Value	Tendency	Significant
SNCA	CD48	1354	> 3	< 0.001	Co-occurrence	Yes
SNCA	TNFRSF14	1454	> 3	0.002	Co-occurrence	Yes
SNCA	CD70	1466	> 3	0.006	Co-occurrence	Yes
SNCA	TNFSF9	1464	> 3	0.008	Co-occurrence	Yes
SNCA	TNFSF4	1399	2.183	0.042	Co-occurrence	Yes
SNCA	TNFSF18	1394	2.087	0.049	Co-occurrence	Yes
SNCA	CD274	1424	<−3	0.586	Mutual exclusivity	No
SNCA	LGALS9	1433	<−3	0.643	Mutual exclusivity	No
SNCA	VTCN1	1438	<−3	0.678	Mutual exclusivity	No
SNCA	PVR	1440	<−3	0.692	Mutual exclusivity	No
SNCA	CD86	1450	<−3	0.767	Mutual exclusivity	No
SNCA	CD200	1456	<−3	0.816	Mutual exclusivity	No
SNCA	ICOSLG	1456	<−3	0.816	Mutual exclusivity	No
SNCA	HHLA2	1459	<−3	0.841	Mutual exclusivity	No

The relationship between SNCA and each immune checkpoint, expressed in terms of co-occurrence and mutual exclusivity. p- value < 0.05 is defined as statistically significant

ISSN: 1471-2407